Want to see UNCY full AI Analyst Report?
Top Page
Unicycive Therapeutics
(NASDAQ:UNCY)
Select Model
Select Model
Rating:46Neutral
Price Target:
$5.50
▲(0.55% Upside)
Action:Reiterated
Date:08/19/26
The score is mainly constrained by weak financial performance—zero revenue, large losses, and significant ongoing cash burn—despite a relatively low-debt and improved equity position. Technicals are mixed with only modest near-term strength, and valuation is limited by negative earnings and no dividend yield support.
Positive Factors
OLC Regulatory Progress
The assigned FDA inspection is a concrete step toward resolving the manufacturing-related regulatory path. If completed successfully, it could support NDA resubmission and reduce a key barrier to converting OLC development into commercial revenue.
Negative Factors
No Commercial Revenue
The absence of recurring product revenue leaves the company dependent on successful OLC development and future commercialization. Persistent large losses also indicate that operating leverage has not yet emerged, limiting financial resilience before approval.
Read all positive and negative factors
Positive Factors
Negative Factors
OLC Regulatory Progress
The assigned FDA inspection is a concrete step toward resolving the manufacturing-related regulatory path. If completed successfully, it could support NDA resubmission and reduce a key barrier to converting OLC development into commercial revenue.
Read all positive factors
Unicycive Therapeutics (UNCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$143.73M
Dividend YieldN/A
Average Volume (3M)749.18K
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue GrowthN/A
EPS Growth43.63%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.67
Shares Outstanding27,855,257
10 Day Avg. Volume637,818
30 Day Avg. Volume749,184
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-2.92
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.83Price Target Upside372.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$2.85M
Unicycive Therapeutics Business Overview & Revenue Model
Company Description
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patien...
How the Company Makes Money
Unicycive is a clinical-stage biopharmaceutical company and, based on publicly available information up to my knowledge cutoff, it has not had a material, recurring commercial product revenue stream because its lead candidate (OLC) has been in dev...
Unicycive Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 675.00K | 951.00K | 0.00 |
| Gross Profit | -211.00K | -572.00K | 0.00 | 675.00K | 951.00K | 0.00 |
| EBITDA | -34.52M | -25.91M | -36.23M | -30.18M | -17.89M | -9.38M |
| Net Income | -35.22M | -26.55M | -36.73M | -30.54M | -18.06M | -10.02M |
Balance Sheet | ||||||
| Total Assets | 72.03M | 49.13M | 31.67M | 14.19M | 2.82M | 18.74M |
| Cash, Cash Equivalents and Short-Term Investments | 61.42M | 41.27M | 26.14M | 9.70M | 455.00K | 16.58M |
| Total Debt | 671.00K | 199.00K | 773.00K | 811.00K | 201.00K | 335.00K |
| Total Liabilities | 18.76M | 18.94M | 24.24M | 18.00M | 3.28M | 2.26M |
| Stockholders Equity | 53.27M | 30.20M | 7.43M | -3.81M | -466.00K | 16.48M |
Cash Flow | ||||||
| Free Cash Flow | -27.85M | -31.34M | -28.65M | -18.30M | -15.65M | -5.80M |
| Operating Cash Flow | -27.84M | -31.32M | -28.57M | -18.28M | -15.65M | -5.77M |
| Investing Cash Flow | -17.25M | -12.10M | -72.00K | -12.00K | -2.00K | -29.00K |
| Financing Cash Flow | 66.95M | 46.47M | 45.09M | 27.54M | -471.00K | 22.38M |
Unicycive Therapeutics Technical Analysis
Negative
5.47
Price Trends
5.32
Negative
6.44
Negative
6.42
Negative
Market Momentum
-0.09
Positive
41.83
Neutral
22.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UNCY, the sentiment is Negative. The current price of 5.47 is above the 20-day moving average (MA) of 5.35, above the 50-day MA of 5.32, and below the 200-day MA of 6.42, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 41.83 is Neutral, neither overbought nor oversold. The STOCH value of 22.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UNCY.
Unicycive Therapeutics Risk Analysis
Unicycive Therapeutics disclosed 56 risk factors in its most recent earnings report. Unicycive Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Unicycive Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $90.71M | 0.83 | 103.52% | ― | 15.46% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $143.73M | -3.00 | -88.81% | ― | ― | 43.63% | |
46 Neutral | $121.52M | -0.98 | -320.60% | ― | -10.30% | 84.17% | |
46 Neutral | $140.13M | -9.40 | -41.15% | ― | -100.00% | 64.23% | |
44 Neutral | $28.67M | -0.64 | -202.14% | ― | ― | 73.69% |
* Healthcare Sector Average
UNCY
Unicycive Therapeutics
5.03
0.74
17.25%
CVM
Cel-Sci
1.65
-8.03
-82.95%
FBIO
Fortress Biotech
2.71
-1.15
-29.79%
CBUS
Cibus
1.61
0.22
15.83%
EQ
Equillium
2.41
0.57
30.98%
Unicycive Therapeutics Corporate Events
Financial Disclosures
Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position
Neutral
Jul 2, 2026
As of June 30, 2026, Unicycive Therapeutics reported an unaudited ending cash balance of approximately $61.4 million, reflecting its liquidity position at the close of the second quarter of 2026. The company emphasized that these preliminary finan...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Unicycive Expands At-The-Market Equity Offering Program
Neutral
Jun 5, 2026
Unicycive Therapeutics, Inc. expanded its existing at-the-market equity program originally established in November 2024 with Guggenheim Securities, LLC, increasing the maximum aggregate offering size of its common stock from $100 million to $150 m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.